Cargando…

Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice

BACKGROUND AND AIMS: This retrospective review of patients with recurrent glioblastoma treated at the Preston Robert Tisch Brain Tumor Center investigated treatment patterns, survival, and safety with bevacizumab in a real‐world setting. METHODS: Adult patients with glioblastoma who initiated bevaci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Desjardins, Annick, Herndon, James E., McSherry, Frances, Ravelo, Arliene, Lipp, Eric S., Healy, Patrick, Peters, Katherine B., Sampson, John H., Randazzo, Dina, Sommer, Nicolas, Friedman, Allan H., Friedman, Henry S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482327/ https://www.ncbi.nlm.nih.gov/pubmed/31049419 http://dx.doi.org/10.1002/hsr2.114

Ejemplares similares

Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis
por: Lee, Jessica W., et al.
Publicado: (2021)

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma
por: Ghiaseddin, Ashley, et al.
Publicado: (2017)

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
por: Affronti, Mary Lou, et al.
Publicado: (2018)

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab
por: Affronti, Mary Lou, et al.
Publicado: (2016)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
por: Lou, Emil, et al.
Publicado: (2013)

Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
por: Chen, Clara, et al.
Publicado: (2015)

Adjunctive perampanel for glioma-associated epilepsy()
por: Dunn-Pirio, Anastasie M., et al.
Publicado: (2018)

Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With or Without Radiation Therapy: A 25-Year Retrospective Analysis of a Single-Institution Experience
por: Kent, Collin L., et al.
Publicado: (2021)

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
por: Gromeier, Matthias, et al.
Publicado: (2021)

Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis
por: Kang, Jennifer H, et al.
Publicado: (2021)

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
por: Reardon, D A, et al.
Publicado: (2009)

The role of chemotherapy in the treatment of central neurocytoma
por: Johnson, Margaret O, et al.
Publicado: (2019)

A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma
por: Sampson, John H., et al.
Publicado: (2012)

Tetanus toxoid and CCL3 improve DC vaccines in mice and glioblastoma patients
por: Mitchell, Duane A., et al.
Publicado: (2015)

Insomnia and its associations in patients with recurrent glial neoplasms
por: Robertson, Matthew E., et al.
Publicado: (2016)

CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL
por: Thompson, Eric, et al.
Publicado: (2020)

First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices
por: Lunacsek, Orsolya E., et al.
Publicado: (2016)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data
por: Bota, Daniela A, et al.
Publicado: (2021)

EPCT-01. A NOVEL PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL
por: Thompson, Eric, et al.
Publicado: (2021)

Oncologists’ Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey
por: Shah-Manek, Bijal, et al.
Publicado: (2018)

Bevacizumab for the Treatment of Glioblastoma
por: Gil-Gil, Miguel J., et al.
Publicado: (2013)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

SPCR-03 NEUROCOGNITIVE OUTCOMES FROM PHASE 1 TRIAL OF BMX-001 IN COMBINATION WITH CONCURRENT RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA PATIENTS
por: Peters, Katherine, et al.
Publicado: (2022)

Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study
por: Walker, Mark S., et al.
Publicado: (2017)

Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011)

A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors
por: Kanaly, Charles W., et al.
Publicado: (2011)

Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence
por: Campbell, Jonathan D, et al.
Publicado: (2009)

Interstitial chemotherapy with biodegradable BCNU (Gliadel(®)) wafers in the treatment of malignant gliomas
por: Bota, Daniela A, et al.
Publicado: (2007)

The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
por: Carvalho, Bruno, et al.
Publicado: (2021)

EPCT-13. CMV PP65 RNA-PULSED DENDRITIC CELL VACCINES FOR PEDIATRIC GLIOBLASTOMA AND MEDULLOBLASTOMA: PHASE I TRIAL RESULTS
por: Landi, Daniel, et al.
Publicado: (2020)

Single fraction stereotactic radiosurgery for multiple brain metastases
por: Limon, Dror, et al.
Publicado: (2017)

Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models
por: Keir, Stephen T., et al.
Publicado: (2018)

Role of bevacizumab therapy in the management of glioblastoma
por: Peak, Scott J, et al.
Publicado: (2010)

Bevacizumab for Glioblastoma—A Promising Drug or Not?
por: Nagane, Motoo, et al.
Publicado: (2013)

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
por: Burger, Michael C., et al.
Publicado: (2017)

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
por: Diplas, Bill H., et al.
Publicado: (2018)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
por: She, Lei, et al.
Publicado: (2022)

Spinal Dissemination of Intracranial Glioblastoma in Bevacizumab Era: a Potential Bevacizumab-induced Mechanism
por: Kaloshi, Gentian, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v9j525vvqmccbd2ovuthrc1drl